Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial.

Huang AJ, Hess R, Arya LA, Richter HE, Subak LL, Bradley CS, Rogers RG, Myers DL, Johnson KC, Gregory WT, Kraus SR, Schembri M, Brown JS.

Am J Obstet Gynecol. 2012 May;206(5):444.e1-11. doi: 10.1016/j.ajog.2012.03.002.

2.

Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.

Chapple C, Oelke M, Kaplan SA, Scholfield D, Arumi D, Wagg AS.

Curr Med Res Opin. 2015 Jun;31(6):1201-43. doi: 10.1185/03007995.2015.1032917. Review.

PMID:
25798911
3.

Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.

Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, Sebastianelli A, Salvi M, Oelke M, Gravas S, Carini M, Serni S.

BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84. Review.

4.

Mixed incontinence: current evidence and future perspectives.

Khullar V, Cardozo L, Dmochowski R.

Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. Review.

PMID:
20432324
5.

Fesoterodine.

McKeage K, Keating GM.

Drugs. 2009;69(6):731-8. doi: 10.2165/00003495-200969060-00006. Review.

PMID:
19405552
6.

Considerations for the management of urgency symptoms in patients with overactive bladder syndrome.

Cardozo LD, Van Kerrebroeck PE, Staskin DR.

World J Urol. 2009 Dec;27(6):755-63. doi: 10.1007/s00345-009-0455-4. Review.

PMID:
19690868
7.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963

Supplemental Content

Support Center